PCI Synthesis Sponsors Second Annual Massachusetts CRO/CMO Symposium
“Greater Boston is home to one of the world’s premier biotech and health science clusters, with world-class hospitals, academic institutions and innovative manufacturers and businesses,” said Edward S. Price, CEO, PCI Synthesis, and co-chair of the MassBio CRO/CMO cluster. “The Massachusetts CRO/CMO community is becoming a leading source of employment and is playing a major part in developing new pharmaceuticals across a broad range of therapeutic classes. The symposium is designed to bring together the thought leaders, influencers and partners who can help shape the future of not only the cluster but the industry itself.”
The goal of the symposium, themed “Accelerating Drug Development,” is to demonstrate through a series of case presentations, interactive panel discussions, and table top exhibits by more than 40 local technical service providers how deep and valuable this robust and comprehensive CRO and CMO community is to the health science ecosystem in Massachusetts and across the nation as the pharmaceutical industry re-invents itself. Heightened regulatory scrutiny, limited funding sources and emerging business models are changing the shape of the industry, and evoke much discussion across all areas of the market. If the inaugural 2012 event is any indication, the symposium will become a primary discussion ground for these and other issues that matter most in the industry. The 2012 symposium proved to be a resounding success, with attendance 30 percent higher than expected and thought-provoking keynotes from industry and government luminaries.
For more information about the symposium, a detailed agenda, a speaker list and registration information, please visit: http://bit.ly/YewQME.
About PCI Synthesis
PCI Synthesis is a 13-year-old custom chemical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products. A contract manufacturing organization (CMO), PCI provides emerging and mid-sized pharmaceutical companies access to the expertise needed to develop and manufacture complex small molecules and APIs used in generic pharmaceuticals. To learn more about PCI Synthesis, its proprietary NCE development activities and process R&D capabilities please visit www.pcisynthesis.com.